Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$2 Mln
P/E Ratio
--
P/B Ratio
0.29
Industry P/E
--
Debt to Equity
0
ROE
-1.22 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-674.15
CFO
$-97.95 Mln
EBITDA
$-82.89 Mln
Net Profit
$-74.08 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Allarity Therapeutics Inc (ALLR)
| -17.95 | 2.71 | -6.80 | -90.68 | -97.72 | -- | -- |
|
BSE Sensex*
| -1.98 | 1.27 | -1.72 | 6.37 | 9.85 | 20.72 | 10.50 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
|
|---|---|---|
|
Allarity Therapeutics Inc (ALLR)
| -92.77 | -99.87 |
|
S&P Small-Cap 600
| 7.01 | 13.89 |
|
BSE Sensex
| 8.10 | 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.18 | 10,372.39 | 21.06 | 23.13 | |
| 32.45 | 12,882.28 | -- | -28.77 | |
| 110.07 | 10,998.29 | 33.53 | 14.16 | |
| 73.45 | 7,759.66 | 34.18 | 19.71 |
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include... Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts. Address: 24 School Street, Boston, MA, United States, 02108 Read more
Founder, CEO, Senior VP of Investor Relations & Director
Mr. Thomas H. Jensen
Founder, CEO, Senior VP of Investor Relations & Director
Mr. Thomas H. Jensen
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Allarity Therapeutics Inc (ALLR) stood at $ 28 Mln as on 30-Sep-24
The share price of Allarity Therapeutics Inc (ALLR) is $0.96 (NASDAQ) as of 20-Mar-2025 16:19 EDT. Allarity Therapeutics Inc (ALLR) has given a return of -97.72% in the last 3 years.
Allarity Therapeutics Inc (ALLR) has a market capitalisation of $ 2 Mln as on 20-Mar-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Allarity Therapeutics Inc (ALLR) is 0.29 times as on 20-Mar-2025, a 89% discount to its peers’ median range of 2.71 times.
Since, TTM earnings of Allarity Therapeutics Inc (ALLR) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Allarity Therapeutics Inc (ALLR) and enter the required number of quantities and click on buy to purchase the shares of Allarity Therapeutics Inc (ALLR).
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts. Address: 24 School Street, Boston, MA, United States, 02108
The CEO & director of Mr. Thomas H. Jensen. is Allarity Therapeutics Inc (ALLR), and CFO & Sr. VP is Mr. Thomas H. Jensen.
There is no promoter pledging in Allarity Therapeutics Inc (ALLR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,168
|
|
|
1,141
|
|
|
1,072
|
|
|
1,045
|
| Allarity Therapeutics Inc (ALLR) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-9886.16
|
|
Net Margin(%)
|
-8636.61
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Allarity Therapeutics Inc (ALLR) was $0 Mln.
$-0.04
(
